Cyclacel Stocks List Ranked for 2024 | NYSE,

Symbol	Grade	Name	% Change
CASI	D	CASI Pharmaceuticals, Inc.	0.75
CYCCP	F	Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock	0.00
CYCC	F	Cyclacel Pharmaceuticals, Inc.	-0.54

Related Industries: Biotechnology

Date	Stock	Title
Nov 17	CASI	CASI Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
Nov 15	CASI	CASI Pharmaceuticals reports Q3 results
Nov 15	CASI	CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results
Nov 15	CYCCP	Cyclacel Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations
Nov 15	CYCC	Cyclacel Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations
Nov 14	CYCC	Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds
Nov 14	CYCCP	Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds
Nov 14	CYCC	Why DLocal Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Nov 14	CASI	Earnings Scheduled For November 14, 2024
Nov 13	CYCCP	Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds
Nov 13	CYCC	Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds
Nov 13	CASI	CASI Pharmaceuticals Q3 Earnings Preview

Cyclacel: Cyclacel Pharmaceuticals Inc. is a biotechnology firm based in Dundee, Scotland, and Short Hills, New Jersey, developing cancer drugs and treatments. Cyclacel was founded in 1996 by David Lane, Merlin Ventures and Cancer Research Campaign Technology with the University of Dundee and the University of Glasgow.
Major shareholders include Goldman Sachs Group, Tang Capital Management, Redmile Group and Ayer Capital Management.
The firm is developing "mechanism-targeted drugs" to help in the fight of cancer, and other serious illness, such as diabetes and HIV.